AzTrials
AzTrials

ST Elevation Myocardial Infarction (STEMI)EasyNCT07325955

Effect of Long Term Trimetazidine Treatment on Final Myocardial Fibrosis for ST Eleviation Myocardial Infarction

An observational study of ST Elevation Myocardial Infarction (STEMI), run by Chinese PLA General Hospital at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Trimetazidine is a agent promoting glucose utilization by limiting fatty-acid oxidation.Trimetazidine could improve cardiac function in patients with ischemic heart disease. We aimed to explore effect of Trimetazidine on final myocardial fibrosis for patients with ST-elevation myocardial infarction (STEMI) in real… Read more about this study

Who is it for?
Ages 18 to 80 years
How many people
194 participants
Where
1 siteChina
Study dates
1 Oct 2020to 1 Dec 2024
How long will I take part?
6 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Study participants were recruited from the Chinese PLA general hospital in Beijing

Who may be able to join

  • Diagnosed STEMI patients within one day after reperfusion threapy; Have performed the primary PCI procedure; Sign the informed consent form for this cohort study

Who cannot join

  • Mechanical complications; Cardiogenic shock; Malignant tumors, severe infection, hepatic or renal failure, respiratory failure, or other short-term progressive diseases

Trial locations and contacts

1 site in 1 country.

China1 site

  • Chinese PLA general hospital

    Beijing, Haidian, 100853

Other trials in China

About this study

Official title: Effect of Long Term Trimetazidine Treatment on Myocardial Final Fibrosis for Acute Myocardial Infarction

Trimetazidine is a agent promoting glucose utilization by limiting fatty-acid oxidation.Trimetazidine could improve cardiac function in patients with ischemic heart disease. We aimed to explore effect of Trimetazidine on final myocardial fibrosis for patients with ST-elevation myocardial infarction (STEMI) in real world clinical practice. In this observational study, we investigated the effect of long-term treatment with trimetazidine on the final extent of myocardial fibrosis measured by cardiac magnetic resonance 6 months after infarction in real world clinical practice.

Read the detailed description

This study is an prospective observational real-world clinical research. We evaluated the effect of long term trimetazidine treatment after the primary percutaneous coronary intervention (PCI), the myocardial infarction size in STEMI patients could be further reduced by metabolic regulation therapy. This study contributes to the development of standardized treatment procedure for STEMI patients.

Keywords
Acute myocardial infarction, Trimetazidine, Metabolic therapy
Medical subject headings
ST Elevation Myocardial Infarction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07325955
Study groupRoleWhat they receive
Trimetazidine treatment groupPatients with trimetazidine treatment
Control groupPatients without Trimetazidine treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. myocardial fibrosis measured by cardiac magnetic resonance imaging

    Delayed enhancement of cardiac magnetic resonance imaging showed the myocardial fibrosis after infarction

    Measured: 6 months after infarction

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jan 2026
  2. Study start1 Oct 2020
  3. Primary completion1 Jul 2024
  4. Study completion1 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
194 participants (actual)
Target duration
6 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07325955
Sponsor's protocol ID
TMZAMI002
Other IDs
SF2020-2-5012
Acronym
Easy
Status last verified
Dec 2025
First submitted
25 Dec 2025
Last updated
8 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Demirelli S, Karakelleoglu S, Gundogdu F, Tas MH, Kaya A, Duman H, Degirmenci H, Hamur H, Simsek Z. The Impact of Trimetazidine Treatment on Left Ventricular Functions and Plasma Brain Natriuretic Peptide Levels in Patients with Non-ST Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Korean Circ J. 2013 Jul;43(7):462-7. doi: 10.4070/kcj.2013.43.7.462. Epub 2013 Jul 31.

    PubMed 23964292

  • Shehata M. Cardioprotective Effects of Oral Trimetazidine in Diabetic Patients With Anterior Wall Myocardial Infarction Treated with Thrombolysis. Cardiol Res. 2014 Apr;5(2):58-67. doi: 10.14740/cr330w. Epub 2014 May 15.

    PubMed 28392876

  • Li R, Tang X, Jing Q, Wang Q, Yang M, Han X, Zhao J, Yu X. The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI. Am J Emerg Med. 2017 Nov;35(11):1657-1661. doi: 10.1016/j.ajem.2017.05.024. Epub 2017 May 23.

    PubMed 28587952

  • Li Y, Wang D, Hu C, Zhang P, Zhang D, Qin S. Efficacy and Safety of Adjunctive Trimetazidine Therapy for Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. Cardiology. 2016;135(3):188-195. doi: 10.1159/000446640. Epub 2016 Jul 15.

    PubMed 27415810

  • Banach M, Rysz J, Goch A, Mikhailidis DP, Rosano GM. The role of trimetazidine after acute myocardial infarction. Curr Vasc Pharmacol. 2008 Oct;6(4):282-91. doi: 10.2174/157016108785909788.

    PubMed 18855716

  • El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005;5(4):271-8. doi: 10.2165/00129784-200505040-00006.

    PubMed 15984909

  • Kim JS, Kim CH, Chun KJ, Kim JH, Park YH, Kim J, Choi JH, Lee SH, Kim EJ, Yu DG, Ahn EY, Jeong MH. Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry. Clin Res Cardiol. 2013 Dec;102(12):915-22. doi: 10.1007/s00392-013-0611-0. Epub 2013 Aug 28.

    PubMed 23982468

  • Bonello L, Sbragia P, Amabile N, Com O, Pierre SV, Levy S, Paganelli F. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart. 2007 Jun;93(6):703-7. doi: 10.1136/hrt.2006.107524. Epub 2007 May 8.

    PubMed 17488771

  • Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006 Sep 5;48(5):992-8. doi: 10.1016/j.jacc.2006.03.060. Epub 2006 Aug 17.

    PubMed 16949492

  • Singh D, Oladimeji-Salami J, Akindele AJ. New insights on pharmacological and therapeutic potentials of trimetazidine beyond anti-anginal drug: A comprehensive review. Eur J Pharmacol. 2024 Dec 15;985:177062. doi: 10.1016/j.ejphar.2024.177062. Epub 2024 Oct 19.

    PubMed 39427862

Questions about this trial

What is this clinical trial studying?

An observational study of ST Elevation Myocardial Infarction (STEMI), run by Chinese PLA General Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

myocardial fibrosis measured by cardiac magnetic resonance imaging (time frame: 6 months after infarction). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07325955, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in